Schizophrenia: synthetic strategies and recent advances in drug design

about

Schizophrenia: synthetic strategies and recent advances in drug design

Item

http://www.wikidata.org/entity/Q57393544

description

im Mai 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 16 March 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в травні 2018

@uk

name

Schizophrenia: synthetic strategies and recent advances in drug design

@en

Schizophrenia: synthetic strategies and recent advances in drug design

@nl

type

Item

label

Schizophrenia: synthetic strategies and recent advances in drug design

@en

Schizophrenia: synthetic strategies and recent advances in drug design

@nl

prefLabel

Schizophrenia: synthetic strategies and recent advances in drug design

@en

Schizophrenia: synthetic strategies and recent advances in drug design

@nl

P1476

Schizophrenia: synthetic strategies and recent advances in drug design

@en

P2093

Maria Azmanova

http://www.w3.org/2001/XMLSchema#string

Nicolas P E Barry

http://www.w3.org/2001/XMLSchema#string

P2860

The dopamine hypothesis of schizophrenia: version III--the final common pathway

Meta-analysis of the acute effects of nicotine and smoking on human performance.

Increasing off-label use of antipsychotic medications in the United States, 1995-2008

Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials.

Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling

Positive allosteric modulators of 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid receptors belonging to 4-cyclopropyl-3,4-dihydro-2h-1,2,4-pyridothiadiazine dioxides and diversely chloro-substituted 4-cyclopropyl-3,4-dihydro-2H-1,2,4-benz

A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits

Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency

The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice

Schizophrenia.

P304

759-782

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1039/C7MD00448F

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Anaïs Pitto-Barry

Nicolas P.E. Barry

Maria Azmanova

P577

2018-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30108966

http://www.w3.org/2001/XMLSchema#string

P921

schizophrenia

P932

6072500

http://www.w3.org/2001/XMLSchema#string